Mohamed Ali, MD
Internal Medicine · Florissant, MONPI 1285607135
Payments from drug & device makers
Across 159 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$595
- Lilly USA, LLC$270
- Amgen$215
- Biosense Webster, Inc.$197
- Novartis$179
- Astellas Pharma US Inc$174
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,17997%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 29 | $595 |
| Lilly USA, LLC | 15 | $270 |
| Amgen | 12 | $215 |
| Biosense Webster, Inc. | 2 | $197 |
| Novartis | 10 | $179 |
| Astellas Pharma US Inc | 5 | $174 |
| Boehringer Ingelheim | 10 | $162 |
| Medtronic | 5 | $138 |
| Novo Nordisk | 9 | $135 |
| Exact Sciences | 8 | $122 |
| AstraZeneca | 6 | $118 |
| Integra Lifesciences Corporation | 1 | $112 |
| AbbVie | 4 | $106 |
| GSK | 6 | $92 |
| Pfizer | 5 | $85 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Ironwood Pharmaceuticals, Inc | 3 | $60 |
| Johnson & Johnson | 3 | $58 |
| Merck | 3 | $54 |
| Dexcom, Inc. | 4 | $51 |
| Edwards Lifesciences | 2 | $46 |
| Abbott | 2 | $39 |
| Boston Scientific | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNIGRAFT$112
- PRIMATRIX$112
- MEDIHONEY$112
- TCC-EZ$112
- AMNIOEXCEL$112
- Puraply Antimicrobial$104
How this compares
$3,274 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 347 | $162,627 |
| JardianceEmpagliflozin | 78 | $74,119 |
| FarxigaDapagliflozin Propanediol | 76 | $74,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $63,934 |
| JanuviaSitagliptin Phosphate | 69 | $61,120 |
| CreonLipase/Protease/Amylase | 28 | $59,262 |
| XifaxanRifaximin | 18 | $49,483 |
| OzempicSemaglutide | 45 | $45,221 |
| XareltoRivaroxaban | 54 | $37,099 |
| LinzessLinaclotide | 26 | $24,408 |
| TradjentaLinagliptin | 47 | $23,019 |
| MounjaroTirzepatide | 15 | $21,848 |
| MyrbetriqMirabegron | 30 | $19,322 |
| EntrestoSacubitril/Valsartan | 29 | $13,733 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $13,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $162,627347 claims |
| Boehringer IngelheimJardiance, Tradjenta | $162 | $97,138125 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy | $92 | $87,444132 claims |
| AbbVieCreon, Linzess | $106 | $83,66954 claims |
| AstraZenecaFarxiga | $118 | $74,11376 claims |
| MerckJanuvia | $54 | $61,12069 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $29 | $49,48318 claims |
| Novo NordiskOzempic | $135 | $45,22145 claims |
| Johnson & JohnsonXarelto | $58 | $37,09954 claims |
| Sanofi-aventis U.S. LLCMultaq, Soliqua 100-33 | $13 | $23,06828 claims |
| Lilly USA, LLCMounjaro | $270 | $21,84815 claims |
| Astellas Pharma US IncMyrbetriq | $174 | $19,32230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Florissant
- Kim McDonaldFlorissant$206K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.